Globus Medical GMED continues to gain from surging demand for its Musculoskeletal Solutions products. However, a challenging macroeconomic scenario continues to plague Globus Medical. The stock ...

Globus Medical, Inc.’s GMED growth in the third quarter can be attributed to the robust prospect in the musculoskeletal space. The company’s merger with NuVasive is expected to generate ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target of $100.00. The company’s shares closed last ...

The company currently has its sales operations distributed across 51 counties worldwide. GMED is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick ...

In a report released today, David Saxon from Needham maintained a Hold rating on Globus Medical (GMED – Research Report). The company’s shares opened today at $92.41. Leverage the power of ...

The company currently has its sales operations distributed across 51 counties worldwide. GMED boasts a Growth Style Score of A and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating.